Page last updated: 2024-11-04

n,n-dimethylaniline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N,N-dimethylaniline: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dimethylaniline : A methylaniline carrying at least two methyl groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

N,N-dimethylaniline : A tertiary amine that is aniline in which the amino hydrogens are replaced by two methyl groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID949
CHEMBL ID371654
CHEBI ID16269
SCHEMBL ID8277
MeSH IDM0064226

Synonyms (100)

Synonym
BIDD:ER0332
LS-13434
versneller nl 63/10
nsc-7195
n,n-(dimethylamino)benzene
dwumetyloanilina
nci-c56428
wln: 1n1 & r
(dimethylamino)benzene
dimethylphenylamine
n,n-dimethylphenylamine
dimethylaniline
nsc7195
n,n-dimethylbenzeneamine
CHEBI:16269 ,
n,n-dimethyl-n-phenylamine
einecs 204-493-5
nsc 7195
un2253
nl 63-10p
ai3-17284
dwumetyloanilina [polish]
ccris 2381
hsdb 1179
dimethylaniline, n,n-
aniline, n,n-dimethyl-
n,n-dimethyl-aniline
benzenamine, n,n-dimethyl-
inchi=1/c8h11n/c1-9(2)8-6-4-3-5-7-8/h3-7h,1-2h
NCGC00090724-01
121-69-7
n,n-dimethylaniline
C02846
n,n-dimethylbenzenamine
dimethylaminobenzene
n,n-dimethylaniline, purified by redistillation, >=99.5%
n-n-dimethylaniline
n,n-dimethylaniline, reagentplus(r), 99%
D0665
D3866
dimethyl-phenyl-amine
smr001252235
MLS002222341
CHEMBL371654
AKOS000119088
NCGC00090724-02
NCGC00090724-03
n,n-dimethylaniline sulfate
unii-7426719369
n,n-dimethylaniline [un2253] [poison]
ec 204-493-5
dtxsid2020507 ,
dtxcid60507
cas-121-69-7
tox21_300036
tox21_201813
NCGC00254056-01
NCGC00259362-01
101357-19-1
STL268843
n,n-dimethylaniline [hsdb]
n,n-dimethylaniline [mi]
n,n-dimethylaniline [ep impurity]
n,n-dimethylaniline [iarc]
SCHEMBL8277
n,n-dimethylaniiine
n, n-dimethylaniline
n,n-dimethylaminobenzene
dimethyl aniline
n,n dimethylaniline
n,n-dimethyaniline
phnme2
phn(ch3)2
n,n-dimethyl aniline
n,n-dimethylamline
n,n-dirnethylaniline
dimethyl-aniline
n,n,-dimethylaniline
n,n-dimethyl-n-phenylamine #
un 2253
n,n-dmethylanlne
J-004597
J-523266
F0001-0348
mfcd00008304
n,n-dimethylaniline, saj first grade, >=99.0%
n,n-dimethylaniline, 99%
n,n-dimethylaniline, lr, >=99%
n,n-dimethylaniline, for synthesis, 99.5%
n,n-dimethylaniline [un2253]
n,n-dimethyl-benzenamine
Q310473
n-dimethylaniline
D95371
86362-18-7
benzenamine,n,n-dimethyl-,oxidized,molybdatetungstatephosphates
EN300-18960
n,n-dimethylaniline (iarc)
(dimetylamino)benzene
n,n-dimethylaniline (ep impurity)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" This suggests that rats are more sensitive than mice to the toxic effect of DMA."( Subchronic (13-week) toxicity studies of N,N-dimethylaniline administered to Fischer 344 rats and B6C3F1 mice.
Abdo, KM; Hiles, R; Jokinen, MP, 1990
)
0.54

Dosage Studied

ExcerptRelevanceReference
" The methanol-insoluble 14C-labelled residues in the gut of rats dosed orally with 14C-SDTFB and 14C-sulmet + nitrite were partially converted to 14C-labelled desaminosulmet, sulmet, N4-acetylsulmet and other unidentified products when fed to recipient rats."( Formation of a diazonium cation intermediate in the metabolism of sulphamethazine to desaminosulphamethazine in the rat.
Feil, VJ; MacGregor, JT; Paulson, GD, 1987
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
dimethylanilineA methylaniline carrying at least two methyl groups.
tertiary amineA compound formally derived from ammonia by replacing three hydrogen atoms by hydrocarbyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
1q21.1 copy number variation syndrome07

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.35480.003245.467312,589.2998AID2517
GLI family zinc finger 3Homo sapiens (human)Potency43.20190.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency36.59180.000221.22318,912.5098AID743035; AID743053
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency78.84090.001022.650876.6163AID1224838
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency9.92550.001530.607315,848.9004AID1224841
estrogen nuclear receptor alphaHomo sapiens (human)Potency54.50980.000229.305416,493.5996AID743069; AID743075; AID743077
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID1134602Hexane-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID1134601Hydrogen-bond basicity, pKHB of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1060462Inhibition of Sir2p in yeast DMY2844 assessed as growth inhibition at 800 uM after 48 hrs2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Evaluation of benzoic acid derivatives as sirtuin inhibitors.
AID1134600Octanol-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (160)

TimeframeStudies, This Drug (%)All Drugs %
pre-199041 (25.63)18.7374
1990's20 (12.50)18.2507
2000's51 (31.88)29.6817
2010's40 (25.00)24.3611
2020's8 (5.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 56.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index56.27 (24.57)
Research Supply Index5.12 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index91.92 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (56.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (1.20%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other164 (98.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]